IQVIA Raises 2025 Revenue Outlook Despite Headwinds

IQVIA Holdings reported first-quarter 2025 revenue of $3.83 billion, a 2.5% increase year-over-year, and adjusted earnings per share of $2.70, both exceeding analyst expectations. However, GAAP net income and diluted EPS declined from the prior year, mainly due to higher restructuring costs, increased stock-based compensation, and losses from unconsolidated affiliates. The Technology & Analytics Solutions segment led with 6.4% revenue growth, while Research & Development Solutions saw marginal gains and Contract Sales & Medical Solutions declined. Management raised its full-year revenue outlook to $16.0–$16.4 billion, citing favorable currency trends and a strong backlog, but kept its adjusted profit guidance unchanged. IQVIA’s stock has underperformed the broader market over the past year as investors weigh ongoing sector challenges, including delayed client decision-making and reduced biotech spending. Despite resilience and strong proposal activity, near-term share performance remains constrained by market and industry headwinds.